AACR Annual Meeting (Event)

Spring Bioscience will exhibit at American Association for Cancer Research (AACR) 2012 Annual Meeting in McCormick Place West, Chicago, IL. All information pertaining to the meeting is available here.

New Products Released in October 2011! (News)

Spring Bioscience is committed to delivering high quality antibodies for your research need and below is the latest expansion of our antibody menu containing 9 new rabbit polyclonal antibodies for your IHC and other applications.

Roche acquires Mariposa Bioscience, Inc. to enhance its R&D capabilities for rabbit monoclonal antibodies (Event)

On Friday, August 20th 2010, Roche completed the acquisition of Mariposa Bioscience, Inc., (Mariposa), a Burlingame, California-based privately held company. This acquisition will enhance Roche Tissue Diagnostics’ antibody development capabilities which are a foundational component of today’s clinical assays and tomorrow’s companion diagnostics. 
            
Mariposa was founded in 2006 with a small team of antibody and molecular scientists who developed and established proprietary technology to clone monoclonal antibodies directly from peripheral blood B cells of non-rodent species without the need for a hybridoma fusion partner (see explanation below). Rabbit monoclonal antibodies are considered more sensitive in clinical applications than antibodies derived from other species, and Mariposa’s technology develops rabbit monoclonal antibodies more quickly than other companies in the industry. As a result, providing researchers, pathologists and their patients with high specificity, quality results that lead to accurate diagnosis. 
            
Hany Massarany, Head of Roche Tissue Diagnostics said, “We are excited about the addition of Mariposa’s world-class researchers, scientists and technology. Mariposa brings a wealth of expertise that will translate into products which provide both our research and diagnostic customers with strategic and effective antibody biomarkers for assessing protein expression in tissue. With Spring, they will further complement our antibody portfolio with advanced detection and ancillary products that are valuable in field of immunohistochemistry and most importantly with companion diagnostics.” 
            
Mariposa has been collaborating with Spring Bioscience, a wholly-owned subsidiary of Roche Tissue Diagnostics/Ventana, for the past three years. During this period, the two companies have worked together to validate the technology, and develop a series of rabbit monoclonal antibodies. Many of these antibodies have been launched as new in vitro diagnostic products at Roche Tissue Diagnostics. 
            
Dr. Robert Pytela, Co-Founder and CEO of Mariposa said, “Mariposa has had a successful collaboration with Spring over the last three years. Roche is the ideal company to build upon our technology to deliver innovative in vitro diagnostics (IVD) products. Therefore, Mariposa and its shareholders are very pleased to have found a strong partner.” 
            
Mariposa’s employees will move to Spring’s facilities located in Pleasanton, California. “We share Ventana’s commitment to innovate cancer diagnostics for patients battling cancer, and are excited to become part of the Roche group,” stated Dr. Jas Villanueva, Co-Founder and COO of Mariposa.

For further information please see: 
            - Mariposa: http://mariposabio.com
            - Spring: http://www.springbio.com
            - Roche Tissue Diagnostics: http://www.ventana.com

Novel Rabbit Monoclonal Antibodies Technology Established at Spring! (Event)

As of April 2010 Spring Bioscience Corporation successfully developed a novel and robust process for making rabbit monoclonal antibodies.
            
Spring Bioscience has long recognized the benefits of rabbit monoclonal antibodies for their specificity and high affinity which makes them ideally suited to deliver optimal results in immunohistochemistry as well as other immunoassay. Through partnership with collaborators, Spring pioneered a series of rabbit monoclonal antibodies in the immunohistochemistry market. Spring’s SP clones have proven themselves time and time again as gold standards in the immunohistochemistry markers and this breakthrough will serve to further this leadership position. 
            
After nearly a year of internal R&D, our scientists have generated an advanced rabbit monoclonal technology that will allow us to accelerate our delivery of a broader menu of these best-in-class antibodies to the market.